Medtronic plc has announced FDA approval and US launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. It can also record and track patient activity 24/7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs.
Back problems are 1 of the top 10 most expensive medical conditions, with an estimated 30% of the 300,000 patients annually who undergo lumbosacral spine procedures developing chronic intractable pain. Chronic pain can negatively impact all aspects of a person's life, yet it remains under-recognized and undertreated. Neurostimulation has been proven to provide effective long-term pain relief and improve quality of life, in addition to being a treatment option for patients interested in trying a non-drug alternative.
Medtronic plc is headquartered in Dublin, Ireland.
Medtronic announces FDA approval and US launch of next generation spinal cord stimulator for chronic pain management. [news release]. Dublin, Ireland: Medtronic plc. September 18, 2017. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2301240. Accessed September 27, 2017.
This Week's Must Reads
Possible Link: Hepatic Steatosis and Brain Aging, JAMA Neurol; ePub 2017 Nov 20; Weinstein, et al
Neurologic Drug Shortages May Compromise Care, Neurology; ePub 2017 Nov 15; Omorodion, et al
Sleep Fragmentation Linked with PD in Older Adults, Mov Disord; ePub 2017 Oct 30; Sohail, Yu, et al
Dietary Sodium to Potassium Ratio and Stroke Risk, Stroke; ePub 2017 Oct 10; Willey, Gardener, et al
Sleep Apnea Did Not Accelerate Kidney Decline, Sleep; ePub 2017 Nov 3; Canales, Hagen, et al
Must Reads in FDA Actions
FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6
FDA Approves Soliris for Generalized MG, Alexion news release; 2017 Oct 23
FDA Approves Lyrica CR Extended-Release Tablets CV, Pfizer news release; 2017 Oct 12
FDA Approves New Treatment Option for Sleep Apnea, FDA news release; 2017 Oct 6